IDO inhibitors

A pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent, or carrier, and a compound according to formula (VI),

• a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein
• R5 is
• wherein
• R11, R12, R14, and R15 are each independently hydrogen, halogen, cyano, —OR, —SR, —NR2, —C(O)OR, —C(O)NR2, —N(R)S(O)2R, —C(O)RX, —S(O)R, —S(O)2R, —S(O)OR, —S(O)2OR, —S(O)NR2, —S(O)2NR2, —OC(O)R, —OC(O)OR, —OC(O)NR2, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)NR2, —N(R)S(O)R, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl or C1-C6haloalkyl, wherein
• each R is independently hydrogen or RX, wherein —RX is C1-C6 alkyl optionally substituted with 1, 2, 3, or 4 groups which are each independently halogen, cyano, nitro, —OR10, —SR10, —N(R10)2, —C(O)OR10, —C(O)N(R10)2, —C(O)R10, —S(O)R10, —S(O)2R10, —S(O)OR10, —S(O)2OR10, —S(O)N(R10)2, —S(O)2N(R10)2, —OC(O)R10, —OC(O)OR10, —OC(O)N(R10)2, —N(R10)C(O)R10, —N(R10)C(O)OR10, —N(R10)C(O)N(R10)2, —N(R10)S(O)R10, —N(R10)S(O)2R10, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, wherein each R10 is independently hydrogen or C1-C6 alkyl;
• and
• R13 is hydrogen or —SH,
• provided that the compound is not
• 4-phenyl-1H-imidazole;
• 2-(2-(1H-imidazol-5-yl)phenoxy)ethanamine;
• 2-(1H-imidazol-4-yl)-phenylamine;
• 4-(2-isopropoxyphenyl)-1H-imidazole;
• 4-(2-isopropoxy-phenyl)-1H-imidazole;
• 4-(3-aminophenyl)imidazole;
• 4-(3-cyanophenyl)imidazole;
• 4-(3-hydroxy-phenyl)-1H-imidazole;
• 4-(3-trifluoromethyl-phenyl)-1H-imidazole;
• 4-[(pyridin-2-yl)methylphenyl]-1H-imidazole;
• 5-(2-chlorophenyl)-imidazole;
• or
• methyl[3-(1H-imidazol-4-yl)-phenoxy]-acetate.